A Safety, Tolerability, Pharmacokinetics, and Food Impact Phase I Study of GST-HG151 Tablets in Single-dose and Multiple-dose in Healthy Volunteers
Latest Information Update: 04 Apr 2024
At a glance
- Drugs GST HG 151 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Fujian Cosunter Pharmaceutical
Most Recent Events
- 04 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2022).
- 03 May 2022 New trial record